Journals / Namık Kemal Tıp Dergisi / 2020 / Cilt: 8 - Sayı: 2

Association of WWOX Gene Expression with Chronic Lymphocytic Leukemia

WWOX GEN İFADESİNİN KRONİK LENFOSİTİK LÖSEMİ İLE İLİŞKİSİ

Pages
258–263
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Our results showed that WWOX expression was significantly higher in CLL patients compared to healthy control group (P 0.05).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The WW domain-containing oxidoreductase (WWOX) gene is located on chromosome 16q23.3-q24.1 and contains the common chromosomal fragile site, FRA16D.
📊
Key Findings & Data:The WWOX gene encodes a Wwox tumor suppressor protein with a molecular weight of 46 kDa.
💡
Conclusion & Impact:Results: Our results showed that WWOX expression was significantly higher in CLL patients compared to healthy control group (P 0.05).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The WW domain-containing oxidoreductase (WWOX) gene is located on chromosome 16q23.3-q24.1 and contains the common chromosomal fragile site, FRA16D. The WWOX gene encodes a Wwox tumor suppressor protein with a molecular weight of 46 kDa. Loss of heterozygosity (LOH) at the WWOX locus, promoter hypermethylation of the WWOX promoter, and consequently Wwox expression loss or reduction has been reported in a large fraction of many human cancers. Also, recent studies have shown that Wwox deficiency is associated with poor prognosis in various types of cancer. Clinical features and genetic anomalies of chronic lymphocytic leukemia (CLL) are well defined, but molecular details are still under investigation. WWOX expression levels could be a possible biomarker for CLL. As much as we know, there is no evidence for diagnostic and prognostic significance of Wwox in CLL. In our study, we aimed to define the expression levels of WWOX in CLL patients and also to analyze the WWOX expression in CLL patients with regard to their clinical characteristics. Materials and Methods: We performed this study in 40 CLL patients and 26 healthy controls. We analyzed the WWOX expression levels by using reverse transcriptase-quantitative PCR (RT-QPCR). Results: Our results showed that WWOX expression was significantly higher in CLL patients compared to healthy control group (P 0.05). Results: Our results showed that WWOX expression was significantly higher in CLL patients compared to healthy control group (P 0.05). Conclusion: Abnormal transcription variants of WWOX gene can be associated with abnormal protein isoforms and these isoforms can change the tumor suppressive effects of WWOX gene in CLL patients.

Özet

Amaç: WW alanı içeren oksidoredüktaz (WWOX) geni kromozom 16q23.3-q24.1 bölgesinde bulunmaktadır ve yaygın kromozomal frajilbölge, FRA16D, içermektedir. WWOX geni 46 kDa moleküler ağırlığında WWOX tümör baskılayıcı proteini kodlar. Birçok insankanserlerinde WWOX lokusunda heterozigozite kaybı (LOH), WWOX promoter hipermetilasyonu ve sonuç olarak Wwox ifadesi kaybıveya azalması bildirilmiştir. Ayrıca, son çalışmalar çeşitli kanser tiplerinde Wwox eksikliğinin kötü prognoz ile ilişkili olduğunugöstermiştir. Kronik lenfositik löseminin (KLL) klinik özellikleri ve genetik anomalileri iyi tanımlanmıştır, fakat moleküler detaylar halenaraştırılmaktadır. WWOX ifadesi seviyeleri KLL için olası bir biyobelirteç olabilir. Bildiğimiz kadarıyla literatürde KLL’de WWOX’ın tanı veprognostik önemi ile ilgili kanıtlar bulunmamaktadır. Çalışmamızda, KLL hastalarında ve sağlıklı kontrollerde WWOX ifadesi düzeylerinitanımlamayı ve KLL hastalarında WWOX ifadesini klinik özelliklerine göre analiz etmeyi amaçladık.Materyal ve Metot: Bu çalışmayı 40 KLL hastasında ve 26 sağlıklı kontrolde gerçekleştirdik. WWOX ifadesi seviyelerini ters transkriptazkantitatif PCR (RT-QPCR) tekniğini kullanarak analiz ettik.Bulgular: Sonuçlarımız WWOX ifadesinin KLL hastalarında sağlıklı kontrol grubuna göre anlamlı derecede yüksek olduğunu gösterdi(P 0,05).Sonuç: Sonuç olarak, WWOX geninin anormal transkripsiyon varyantları, anormal protein izoformları ile ilişkilendirilebilir ve buizoformlar, KLL hastalarında WWOX geninin tümör baskılayıcı etkilerini değiştirebilir.

🔖

Cite This Article

HANCI, H., TOPÇU, B., AKPINAR, S., BurhanTURGUT, B., BATAR, B. (2020). Association of WWOX Gene Expression with Chronic Lymphocytic Leukemia. Namık Kemal Tıp Dergisi, Cilt: 8 - Sayı: 2, 258–263. https://ajindex.com/articles/340902

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Aldaz CM, Ferguson BW, Abba MC. WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochimica et Biophysica Acta. 2014;1:188-200
  2. Bednarek AJ, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–16q24.1, a region frequently affected in breast cancer. Cancer Research. 2000;60:2140-5
  3. Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarskym Y, Sudol M, Croce CM. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Research 2005;15:6764-72
  4. Schrock MS, Batar B, Lee J, Druck T, Ferguson B, Cho JH ve ark. Wwox-BRCA1 interaction: role in DNA repair pathway choice. Oncogene 2017;36:2215-27
  5. Abu-Odeh M, Salah Z, Herbel C, Hofmann TG, Aqeilan RI. WWOX, the common fragile site FRA16D gene product, regulatesATM activation and the DNA damage response. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:E4716-E4725
  6. Aqeilan RI, Hagan JP, de Bruin A, Rawahneh M, Salah Z, Gaudio E, Siddiqui H, Volinia S, Alder H, Lian JB, Stein GS, Croce CM. Targeted ablation of the WW domaincontaining oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology. 2009;3:1530-5
  7. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copynumber alteration across human cancers. Nature. 2010;18:899–905
  8. Wang X, Chao L, Jin G, Ma G, Zang Y, Sun J. Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumour Biology. 2009;30:8-14, 9. Guo W, Wang G, Dong Y, Guo Y, Kuang G, Dong Z. Decreased expression of WWOX in the development of esophageal squamous cell carcinoma. Moecularl Carcinogenesis. 2013;52:265-74
  9. Nakayama S, Semba S, Maeda N, Matsus